Huons BioPharma
Huons BioPharma is a Korean specialty biopharmaceutical company that develops and commercializes botulinum toxin type A products (HUTOX for export, LIZTOX for Korea) and is expanding into ophthalmology and aesthetics pipelines, serving global markets through exclusive regional licensing partners.
- Company typePrivate
- Founded2021
- HeadquartersSeongnam, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Huons BioPharma does
Huons BioPharma (휴온스바이오파마) is a Korean specialty biopharmaceutical company headquartered in Seongnam, South Korea, focused on botulinum toxin type A products. The company was spun off from Huons Global in April 2021 and operates as a private company, with Huons Global retaining 74.6% ownership and IMeik Technology Development (China) holding a strategic 25.4% stake. Its commercial portfolio consists of two main formulations: HUTOX for export markets and LIZTOX for the domestic Korean market, both built on a patented liquid formulation of botulinum toxin type A that does not require reconstitution prior to injection. Manufacturing is concentrated at the Jecheon Bio Valley facility, which houses three factories with a planned annual capacity of 13.68 million vials.
The company's development pipeline extends the core toxin franchise and adds two adjacent therapeutic areas. HU-045 is a next-generation botulinum toxin currently in Phase 3 trials, leveraging proprietary purification technology. A peptide eye drop program for dry age-related macular degeneration has received funding from the Korea Drug Development Fund (KDDF). MRC101, a body contouring candidate, is being advanced through a partnership with VERNI Aesthetics announced in November 2024. The company has secured regulatory approvals in 15-16 countries, holds EU GMP certification, and received China NMPA approval for HUTOX in January 2026. It earned Korea's 7 Million Dollar Export Tower award in 2025, reflecting export revenue of approximately 13.2 billion KRW (~$9 million USD).
Huons BioPharma's revenue model combines direct product sales with long-dated licensing and royalty arrangements. Three exclusive regional partners anchor the strategy: AquaVIT for North America (contract value approximately 400 billion KRW), HAEMATO PHARM for Europe (approximately 972 billion KRW), and IMeik Technology for China (1.554 trillion KRW strategic investment plus distribution rights). Domestic Korean LIZTOX sales and additional exports across the 15-16 approved countries provide supplementary revenue. The 1.554 trillion KRW IMeik investment is notable not only as a funding event but also as the mechanism that delivered China market access and culminated in the January 2026 NMPA approval, which is positioned as the single largest near-term commercial catalyst.
Huons BioPharma firmographics
Firmographics- Name
- Huons BioPharma
- Legal name
- (주)휴온스바이오파마
- Website
- https://huonsbiopharma.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Huons BioPharma is a Korean specialty biopharmaceutical company that develops and commercializes botulinum toxin type A products (HUTOX for export, LIZTOX for Korea) and is expanding into ophthalmology and aesthetics pipelines, serving global markets through exclusive regional licensing partners.
- Ownership category
- akta.pro rank
Huons BioPharma industry classification
Industry- Product category
- Biopharmaceuticals (Botulinum Toxin Type A)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- High-Potency API (HPAPI) Development & Manufacturing (HLAGAHAC)
- akta.pro secondary industry
- Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)
Keywords
Where Huons BioPharma is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Huons BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Botulinum Toxin Product Sales (Hutox/LIZTOX): Sale of botulinum toxin type A products (Hutox for export, LIZTOX for domestic Korea) in 50, 100, and 200 unit formulations. Products are sold domestically through medical/aesthetic institutions and exported through licensing partners in international markets. The company achieved approximately 9 million USD (~13.2 billion KRW) in exports over the past year, securing product registrations in 15-16 countries.
- Licensing Royalties and Milestone Payments: The company generates revenue through licensing arrangements with regional partners including milestone payments and ongoing royalties. Notable contracts include: AquaVIT Holdings for North America (400 billion KRW total over 10 years including royalties and milestones), HAEMATO PHARM for Europe (972 billion KRW over 10 years including milestones), and IMeik Technology for China (investment of 1.554 trillion KRW + ongoing supply).
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Huons BioPharma product offering
Product offeringCore offering
Huons BioPharma is a Korean specialty biopharmaceutical manufacturer that develops, produces, and sells botulinum toxin type A injectable products (LIZTOX in Korea, Hutox for export) in 50, 100, and 200 unit vial formulations for aesthetic indications (glabellar lines, crow's feet) and therapeutic applications. Beyond its commercial core, the company is advancing a pipeline that includes HU-045 (a next-generation 150kDa purified botulinum toxin to reduce resistance), a peptide-based eye drop for geographic atrophy/dry AMD, and a body-contouring lipolysis product (MRC101) licensed from VERNI Aesthetics. The company sells domestically through medical and aesthetic institutions and internationally through exclusive licensing partners across 15-16 countries.
Product overview
Huons BioPharma is a specialized botulinum toxin company spun off from Huons Global in 2021, focusing on aesthetic and therapeutic botulinum toxin products and bio-pharmaceutical development. The core product portfolio centers on LIZTOX (domestic brand) / HUTOX (export brand), available in 50, 100, and 200 unit formulations for aesthetic applications including glabellar lines and crow's feet lines. The pipeline includes HU-045, a next-generation 150kDa botulinum toxin designed to reduce resistance development, and a peptide-based eye drop for geographic atrophy (dry AMD). Through strategic partnerships, the company has also acquired rights to MRC101, a body contouring product. The company operates manufacturing facilities in Jecheon, Korea with EU GMP-certified second factory, and exports to over 16 countries globally.
Differentiator
Problem solved
Functional benefit
Brands
- Liztox (리즈톡스): Domestic brand name for botulinum toxin type A product for aesthetic use (glabellar lines and crow's feet improvement). Available in 50, 100, and 200 unit formulations.
- Hutox (휴톡스)
Products and services
- LIZTOX Inj. 100 units (export brand: Hutox 100 units) Botulinum toxin type A (Clostridium botulinum toxin type A) injectable, 100 units per vial. Indicated for temporary improvement of moderate to severe glabellar lines (frown lines between the eyebrows) and crow's feet lines associated with orbicularis oculi muscle activity in adults aged 19 to 65. For medical aesthetic clinics, dermatology practices, and hospitals.
- LIZTOX Inj. 200 units (export brand: Hutox 200 units) Botulinum toxin type A injectable, 200 units per vial. Indicated for temporary improvement of moderate to severe glabellar lines and crow's feet lines in adults aged 19 to 65. The higher unit formulation also supports therapeutic indications (post-stroke upper-limb spasticity and masseter hypertrophy) for which Phase 3 clinical trials are ongoing.
- LIZTOX Inj. 50 units (export brand: Hutox 50 units) Botulinum toxin type A injectable, 50 units per vial, for the domestic Korean market under the LIZTOX brand. Indicated for temporary improvement of moderate to severe glabellar lines and crow's feet lines in adults aged 19 to 65.
- HU-045 (Next-Generation Botulinum Toxin) Next-generation botulinum toxin type A purified to contain only the 150kDa neurotoxin protein with non-toxic proteins removed, designed to reduce neutralizing antibody formation and the resistance/tolerance that develops with repeated botulinum toxin treatments. Phase 3 clinical trial approved (November 2023) for moderate-to-severe glabellar line indication, with target indication approval in 2025.
- Peptide Eye Drops for Dry Age-related Macular Degeneration (Geographic Atrophy) Peptide-based ophthalmic therapeutic that selectively blocks inflammatory TLR signaling pathways in the retina. Developed as a non-invasive eye drop alternative to current intravitreal injections for geographic atrophy (late-stage dry AMD). Technology licensed from KIST (Korea Institute of Science and Technology). Selected for KDDF national R&D funding for non-clinical development.
- MRC101 Body Contouring / Lipodissolution Injectable Body contouring / lipodissolution injectable product under development by partner VERNI Aesthetics for aesthetic body contouring indications. Currently in Phase 2a clinical stage. Huons BioPharma holds commercialization and manufacturing rights.
Quantifiable outcome
- Hutox became the seventh botulinum toxin product commercially available in China and the second Korean product after Hugel's Letybo, with China market entry in 2026.
- +4 more outcomes
Companies that use Huons BioPharma
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Huons BioPharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Huons BioPharma partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- IMeik Technology / Huons Humedix Joint SymposiumminorJoint academic symposium in China organized by IMeik (Huons BioPharma's Chinese partner) to officially launch Hutox in China. Huons Humedix supported the event by leveraging its Korean medical professional network to invite speakers and coordinate academic communications. The event featured Dr. Chris Gunwoo Kim of Cellinique Clinic presenting on global botulinum toxin trends and clinical applications.
- Korea Drug Development Fund (KDDF) / National New Drug Development ProjectcoreHuons BioPharma's peptide eye drop candidate for geographic atrophy (dry AMD) was selected for KDDF's '2026 1st National New Drug Development Project for Building a New Drug R&D Ecosystem'. KDDF will provide research funding over 2 years for non-clinical studies toward US Phase 2 IND approval. The company also collaborates with US ophthalmology CRO (ORA) and Korean CMOs for this project. KDDF is a pan-government national R&D initiative (2021-2030) supporting all stages of drug development.
- Al Reyada (Kuwait)minorLocal Kuwaiti partner that collaborated with Huons BioPharma to secure Ministry of Health Kuwait (MOH Kuwait) approval for Hutox 100-unit botulinum toxin product in May 2026. This represents Huons BioPharma's first entry into the GCC (Gulf Cooperation Council) market, serving as a strategic bridgehead for expansion into the broader Middle East and Gulf region.
- Korea Institute of Science and Technology (KIST) - Natural Products Drug Development DivisioncoreTechnology licensing agreement for a peptide therapeutic candidate targeting geographic atrophy (late-stage dry AMD). The technology involves peptides that selectively block inflammatory TLR signaling pathways in the retina. Huons BioPharma acquired exclusive licensing rights to this technology. KIST developed the candidate through animal studies demonstrating therapeutic efficacy in dry AMD mouse models. Domestic and international PCT patents have been filed.
- VERNI Aesthetics (베르니에스테틱스)coreStrategic investment agreement where Huons BioPharma acquired commercialization and manufacturing rights to MRC101 (lipodissolution/body contouring injectable product) through investment. VERNI Aesthetics is a biotech venture founded by dermatologists developing MRC101 currently in Phase 2a clinical stage. Both companies agreed to collaborate on future development of MRC101 follow-on pipelines. This partnership diversifies Huons BioPharma's aesthetic portfolio beyond botulinum toxin.
- HAEMATO PHARM GmbH (Germany)coreExclusive export agreement for Europe (EU 27 countries + UK + Switzerland = 29 countries) for Hutox botulinum toxin. Contract worth 972 billion KRW over 10 years including milestones. HAEMATO PHARM GmbH is a German pharmaceutical company with a specialized aesthetic clinic chain M1 Kliniken AG operating 40+ clinics in Germany and Austria. Company has an in-house RA (Regulatory Affairs) team with extensive local clinical and approval experience. Target: European market entry by 2025.
- IMeik Technology (아이메이커테크놀로지)coreIMeik Technology (stock code: 300896.SZ, Shenzhen Stock Exchange) acquired exclusive import and distribution rights for Huons BioPharma's botulinum toxin products in Greater China (mainland China, Hong Kong, Macau) in 2022. IMeik invested 1,554 billion KRW in Huons BioPharma (535 billion KRW for existing shares + 1,019 billion KRW for new shares through third-party capital increase), giving IMeik a 25.4% stake. IMeik is China's leading aesthetic company with market cap of approximately 26 trillion KRW. IMeik received NMPA approval for Hutox in January 2026 and operates its own dermal filler manufacturing facility and R&D center.
- AquaVIT Holdings LLC (USA)coreLicense-out agreement for North American market (US and North America) for Hutox botulinum toxin product. Contract worth 400 billion KRW over 10 years including royalties and milestones. AquaVIT specializes in botulinum toxin and aesthetic procedures, owns the 'AquaGold' micro-injector device, and has a network of approximately 20,000 medical professionals globally. Key management includes former Botox marketing executives from Allergan. Target: US FDA clinical IND and market entry by 2024.
Scale indicators9 records
Recent moves8 records
Expansion highlights4 records
Huons BioPharma competitors and assessment
Company assessmentDirect peers
- Hugel: Korean botulinum toxin manufacturer whose Letybo became the first Korean Type A botulinum toxin approved in China. Direct competitor in the same product category serving the same aesthetic and therapeutic end markets.
- Daewoong Pharmaceutical: Korean pharmaceutical company that developed Nabota, another Type A botulinum toxin. Direct competitor in the global botulinum toxin market with comparable manufacturing and export footprint.
- Medytox: Korean developer of Meditoxin, an early Korean botulinum toxin product. Direct peer competing in the same Korean and international botulinum toxin segments.
Emerging players
- Evolus: US-based aesthetic company commercializing Jeuveau (prabotulinumtoxinA). Emerging competitor focused on the aesthetic segment, particularly relevant to Huons's North America market entry via AquaVIT.
- Revance Therapeutics: Developer of DaxibotulinumtoxinA (Daxxify), a long-duration botulinum toxin. Emerging player bringing novel formulation technology to the aesthetic category, comparable in spirit to Huons's liquid formulation and HU-045 differentiation efforts.
Broad incumbents
- Allergan Aesthetics (AbbVie): Developer of Botox, the global market-leading botulinum toxin brand. Broad incumbent across aesthetic and therapeutic indications; the primary competitive benchmark for the entire category.
- Merz Pharmaceuticals: Developer of Xeomin/Bocouture, a purified botulinum toxin without complexing proteins. Broad incumbent competing across aesthetic and therapeutic indications globally.
- Ipsen: Global pharmaceutical company marketing Dysport/Azzalure botulinum toxin. Broad incumbent in therapeutic and aesthetic segments; the new Huons CEO previously held a position at Ipsen Korea.
Others
- Humedix (Huons Group affiliate): Huons Group affiliate focused on hyaluronic acid dermal fillers and medical aesthetics. Sister company within Huons Group; comparable customer base and aesthetics channel, supporting Huons BioPharma's China launch through joint symposium activities.
Regional players
- Croma-Pharma: Austrian aesthetics company with botulinum toxin and hyaluronic acid product lines. Regional player concentrated in Europe, comparable in scale and product mix to Huons's early international expansion profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Huons BioPharma social profiles
Digital presenceHuons BioPharma compliance and trust
Trust signalCompliance5 records
Huons BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Huons BioPharma leadership team
Management profileNumber of profiles
Profiles2 records
Huons BioPharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Huons BioPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Huons BioPharma
What does Huons BioPharma do?
Huons BioPharma is a Korean specialty biopharmaceutical manufacturer that develops, produces, and sells botulinum toxin type A injectable products (LIZTOX in Korea, Hutox for export) in 50, 100, and 200 unit vial formulations for aesthetic indications (glabellar lines, crow's feet) and therapeutic applications. Beyond its commercial core, the company is advancing a pipeline that includes HU-045 (a next-generation 150kDa purified botulinum toxin to reduce resistance), a peptide-based eye drop for geographic atrophy/dry AMD, and a body-contouring lipolysis product (MRC101) licensed from VERNI Aesthetics. The company sells domestically through medical and aesthetic institutions and internationally through exclusive licensing partners across 15-16 countries.
Is Huons BioPharma a public or private company?
Huons BioPharma is a private company. It is classified as corporate owned and is currently operating.
When was Huons BioPharma founded?
Huons BioPharma was founded in 2021. It employs 51 to 100 people.
Where is Huons BioPharma based?
Huons BioPharma is headquartered in Seongnam, South Korea, in the Asia region.
How does Huons BioPharma make money?
Two revenue lines are on record. Botulinum Toxin Product Sales (Hutox/LIZTOX) is the primary driver. The others are licensing Royalties and Milestone Payments.
Who are Huons BioPharma's main competitors?
Direct peers on record are Hugel, Daewoong Pharmaceutical and Medytox. Emerging players are Evolus and Revance Therapeutics. Broad incumbents are Allergan Aesthetics (AbbVie), Merz Pharmaceuticals and Ipsen. Humedix (Huons Group affiliate) is listed as an others. Croma-Pharma is listed as a regional player.
Does Huons BioPharma have an API?
No public API is recorded for Huons BioPharma.
What industry is Huons BioPharma in?
Huons BioPharma's product category is Biopharmaceuticals (Botulinum Toxin Type A). Its primary akta.pro industry code is HLAGAHAC, High-Potency API (HPAPI) Development & Manufacturing, with a secondary code of HLAGAGAF, Analytical Development & QC Testing (Release/Stability/Potency). Its NAICS code is 325412 and its SIC code is 2834.